Pfizer (0Q1N) Share Forecast & Price Target

Compare

35 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0Q1N Analyst Ratings

Moderate Buy

5 Buy

10 Hold

0 Sell

Based on 15 analysts giving stock ratings to

Pfizer

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0Q1N Stock 12 Month Forecast

Average Price Target

$28.80

▲(14.92% Upside)

Based on 15 Wall Street analysts offering 12 month price targets for Pfizer in the last 3 months. The average price target is $28.80 with a high forecast of $35.00 and a low forecast of $24.00. The average price target represents a 14.92% change from the last price of $25.06.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"21":"$21","36":"$36","24.75":"$24.8","28.5":"$28.5","32.25":"$32.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$35.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$28.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$24.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[21,24.75,28.5,32.25,36],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.298,26.04430769230769,26.790615384615382,27.536923076923074,28.28323076923077,29.02953846153846,29.775846153846153,30.522153846153845,31.268461538461537,32.01476923076923,32.76107692307692,33.507384615384616,34.253692307692305,{"y":35,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.298,25.567384615384615,25.836769230769228,26.106153846153845,26.37553846153846,26.644923076923074,26.91430769230769,27.183692307692308,27.45307692307692,27.722461538461538,27.991846153846154,28.26123076923077,28.530615384615384,{"y":28.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.298,25.198153846153843,25.098307692307692,24.998461538461537,24.898615384615383,24.79876923076923,24.698923076923077,24.59907692307692,24.499230769230767,24.399384615384616,24.29953846153846,24.199692307692306,24.099846153846155,{"y":24,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":24.117,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 50, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.677,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 43, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.325,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 41, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.613,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.665,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 49, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.835,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 49, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.549,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 57, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.202,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.026,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.254,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.868,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.205,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.298,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$35.00

Average Price Target$28.80

Lowest Price Target$24.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Courtney Breen

Bernstein

$30

Hold

19.71%

Upside

Assigned

12/19/25

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (NASDAQ: BMRN), Lexicon Pharmaceuticals (NASDAQ: LXRX) and Pfizer (NYSE: PFE)

Geoff Meacham

Citi

$26

Hold

3.75%

Upside

Reiterated

12/17/25

Pfizer (PFE) Gets a Hold from Citi

Terence Flynn

Morgan Stanley

$28→$27

Hold

7.74%

Upside

Reiterated

12/17/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Novan (NASDAQ: NOVN) and Pfizer (NYSE: PFE)

Louise Chen

Scotiabank

$30

Buy

19.71%

Upside

Reiterated

12/17/25

Scotiabank Reaffirms Their Buy Rating on Pfizer (PFE)

Akash Tewari

Jefferies

$34

Buy

35.67%

Upside

Reiterated

12/16/25

Analysts' Top Healthcare Picks: Pfizer (PFE), Novan (NOVN)

Chris Schott

J.P. Morgan

$30

Hold

19.71%

Upside

Reiterated

12/16/25

Analysts Conflicted on These Healthcare Names: Pfizer (NYSE: PFE), Novan (NASDAQ: NOVN) and Repligen (NASDAQ: RGEN)

Jason Gerberry

Bank of America Securities

$28

Hold

11.73%

Upside

Reiterated

12/15/25

Pfizer's Hold Rating: Navigating Loss of Exclusivity and Flat Growth Prospects

Evan Seigerman

BMO Capital

$30

Buy

19.71%

Upside

Reiterated

12/10/25

Rajesh Kumar

HSBC

$28→$29

Buy

15.72%

Upside

Reiterated

12/10/25

Pfizer price target raised to $29 from $28 at HSBCPfizer price target raised to $29 from $28 at HSBC

David Risinger

Leerink Partners

$26

Hold

3.75%

Upside

Reiterated

12/09/25

Analysts Offer Insights on Healthcare Companies: Fennec Pharmaceuticals (NASDAQ: FENC) and Pfizer (NYSE: PFE)

Vamil Divan

Guggenheim

$35

Buy

39.66%

Upside

Reiterated

12/09/25

Guggenheim Sticks to Their Buy Rating for Pfizer (PFE)

Kerry Holford

Berenberg Bank

$25

Hold

-0.24%

Downside

Reiterated

11/26/25

Berenberg Bank Reaffirms Their Hold Rating on Pfizer (PFE)

Mohit Bansal

Wells Fargo

$28

Hold

11.73%

Upside

Reiterated

11/25/25

Pfizer (PFE) Gets a Hold from Wells Fargo

Steve Scala

TD Cowen

$30

Hold

19.71%

Upside

Reiterated

11/04/25

Pfizer (PFE) Receives a Hold from TD Cowen

Carter Gould

Cantor Fitzgerald

$24

Hold

-4.23%

Downside

Reiterated

11/04/25

Pfizer (PFE) Gets a Hold from Cantor Fitzgerald

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Courtney Breen

Bernstein

$30

Hold

19.71%

Upside

Assigned

12/19/25

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (NASDAQ: BMRN), Lexicon Pharmaceuticals (NASDAQ: LXRX) and Pfizer (NYSE: PFE)

Geoff Meacham

Citi

$26

Hold

3.75%

Upside

Reiterated

12/17/25

Pfizer (PFE) Gets a Hold from Citi

Terence Flynn

Morgan Stanley

$28→$27

Hold

7.74%

Upside

Reiterated

12/17/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Novan (NASDAQ: NOVN) and Pfizer (NYSE: PFE)

Louise Chen

Scotiabank

$30

Buy

19.71%

Upside

Reiterated

12/17/25

Scotiabank Reaffirms Their Buy Rating on Pfizer (PFE)

Akash Tewari

Jefferies

$34

Buy

35.67%

Upside

Reiterated

12/16/25

Analysts' Top Healthcare Picks: Pfizer (PFE), Novan (NOVN)

Chris Schott

J.P. Morgan

$30

Hold

19.71%

Upside

Reiterated

12/16/25

Analysts Conflicted on These Healthcare Names: Pfizer (NYSE: PFE), Novan (NASDAQ: NOVN) and Repligen (NASDAQ: RGEN)

Jason Gerberry

Bank of America Securities

$28

Hold

11.73%

Upside

Reiterated

12/15/25

Pfizer's Hold Rating: Navigating Loss of Exclusivity and Flat Growth Prospects

Evan Seigerman

BMO Capital

$30

Buy

19.71%

Upside

Reiterated

12/10/25

Rajesh Kumar

HSBC

$28→$29

Buy

15.72%

Upside

Reiterated

12/10/25

Pfizer price target raised to $29 from $28 at HSBCPfizer price target raised to $29 from $28 at HSBC

David Risinger

Leerink Partners

$26

Hold

3.75%

Upside

Reiterated

12/09/25

Analysts Offer Insights on Healthcare Companies: Fennec Pharmaceuticals (NASDAQ: FENC) and Pfizer (NYSE: PFE)

Vamil Divan

Guggenheim

$35

Buy

39.66%

Upside

Reiterated

12/09/25

Guggenheim Sticks to Their Buy Rating for Pfizer (PFE)

Kerry Holford

Berenberg Bank

$25

Hold

-0.24%

Downside

Reiterated

11/26/25

Berenberg Bank Reaffirms Their Hold Rating on Pfizer (PFE)

Mohit Bansal

Wells Fargo

$28

Hold

11.73%

Upside

Reiterated

11/25/25

Pfizer (PFE) Gets a Hold from Wells Fargo

Steve Scala

TD Cowen

$30

Hold

19.71%

Upside

Reiterated

11/04/25

Pfizer (PFE) Receives a Hold from TD Cowen

Carter Gould

Cantor Fitzgerald

$24

Hold

-4.23%

Downside

Reiterated

11/04/25

Pfizer (PFE) Gets a Hold from Cantor Fitzgerald

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Pfizer

1 Month

xxx

Success Rate

16/31 ratings generated profit

Average Return

+0.02%

reiterated a xxx

rating 19 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 51.61% of your transactions generating a profit, with an average return of +0.02% per trade.

3 Months

xxx

Success Rate

24/35 ratings generated profit

Average Return

+2.49%

reiterated a xxx

rating 20 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 68.57% of your transactions generating a profit, with an average return of +2.49% per trade.

1 Year

Vamil DivanGuggenheim

Success Rate

27/35 ratings generated profit

Average Return

+5.39%

reiterated a buy rating 20 days ago

Copying Vamil Divan's trades and holding each position for 1 Year would result in 77.14% of your transactions generating a profit, with an average return of +5.39% per trade.

2 Years

xxx

Success Rate

28/35 ratings generated profit

Average Return

+7.71%

reiterated a xxx

rating 20 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 80.00% of your transactions generating a profit, with an average return of +7.71% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0Q1N Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0Q1N has received 20 Buy Ratings, 32 Hold Ratings, and 0 Sell Ratings. 0Q1N average Analyst price target in the past 3 months is 28.80.

Each month's total comprises the sum of three months' worth of ratings.

0Q1N Financial Forecast

0Q1N Earnings Forecast

Next quarter’s earnings estimate for 0Q1N is $0.59 with a range of $0.44 to $0.84. The previous quarter’s EPS was $0.87. 0Q1N beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year 0Q1N has Performed in-line its overall industry.

0Q1N Sales Forecast

Next quarter’s sales forecast for 0Q1N is $17.04B with a range of $16.13B to $18.39B. The previous quarter’s sales results were $16.65B. 0Q1N beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year 0Q1N has Performed in-line its overall industry.

0Q1N Stock Forecast FAQ

What is GB:0Q1N’s average 12-month price target, according to analysts?

Based on analyst ratings, Pfizer Inc’s 12-month average price target is 28.80.

What is GB:0Q1N’s upside potential, based on the analysts’ average price target?

Pfizer Inc has 14.92% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Pfizer Inc a Buy, Sell or Hold?

Pfizer Inc has a consensus rating of Moderate Buy, which is based on 5 buy ratings, 10 hold ratings and 0 sell ratings.

What is Pfizer Inc’s share price target?

The average share price target for Pfizer Inc is 28.80. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $35.00 ,and the lowest forecast is $24.00. The average share price target represents 14.92% Increase from the current price of $25.06.

What do analysts say about Pfizer Inc?

Pfizer Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of Pfizer Inc?

To buy shares of GB:0Q1N, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Pfizer (0Q1N) Share Forecast & Price Target

0Q1N Analyst Ratings

0Q1N Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Pfizer

0Q1N Analyst Recommendation Trends

0Q1N Financial Forecast

0Q1N Earnings Forecast

0Q1N Sales Forecast

0Q1N Stock Forecast FAQ

Detailed List of Analyst Forecasts